Phase III pivotal study findings in the journal Vaccine showed that two formulations of CSL Biotherapies' influenza virus vaccine AfluriaŽ elicited an immune response (also known as immunogenicity) in healthy adults aged 18 - About the Phase III Study The pivotal study was a National Institutes (Source: Health News from Medical News Today)
Original source: http://www.medicalnewstoday.com/articles/120385.php